Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Precision NanoSystems","sponsor":"CanSino Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CanSino, Precision NanoSystems to co-develop COVID-19 RNA Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Precision NanoSystems","sponsor":"Sirnaomics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sirnaomics and Precision NanoSystems Have Formed a Partnership","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Precision NanoSystems","sponsor":"Government of Canada","pharmaFlowCategory":"D","amount":"$18.2 million","upfrontCash":"Undisclosed","newsHeadline":"Precision NanoSystems Will Receive $18.2 Million from the Government of Canada to Develop an RNA Vaccine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Precision NanoSystems","sponsor":"Replicate Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Precision NanoSystems and Replicate Bioscience in Licensing Deal to Scale up Genomic Medicines","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Precision NanoSystems

    Menu

    Precision NanoSystems

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Precision NanoSystems

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Precision NanoSystems and Replicate Bioscience in Licensing Deal to Scale up Genomic Medicines

              Details:

              In this licensing agreement, PNI will provide lipid nanoparticle solutions for scale-up and manufacture of up to 15 Replicate srRNA therapeutics, including RBI-1000. The terms include aggregated milestone fees, royalties, and sublicensing income sharing.

              Lead Product(s): RBI-1000

              Therapeutic Area: Oncology Product Name: RBI-1000

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Replicate Bioscience

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement July 26, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Precision NanoSystems

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Precision NanoSystems Will Receive $18.2 Million from the Government of Canada to Develop an RNA Vaccine for COVID-19

              Details:

              PNI will use the investment to advance a best-in-class COVID-19 mRNA vaccine candidate to clinical trials.

              Lead Product(s): COVID-19 mRNA vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Vaccine

              Partner/Sponsor/Collaborator: Government of Canada

              Deal Size: $18.2 million Upfront Cash: Undisclosed

              Deal Type: Funding October 23, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Precision NanoSystems

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sirnaomics and Precision NanoSystems Have Formed a Partnership

              Details:

              The collaboration aims at executing NanoAssemblr platform license and supply agreement, and successful production of multiple batches of Sirnaomics STP705 and STP707, for ongoing IND enabling safety and toxicity studies, as well as several clinical studies.

              Lead Product(s): Cotsiranib

              Therapeutic Area: Oncology Product Name: STP705

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Sirnaomics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership June 20, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Precision NanoSystems

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CanSino, Precision NanoSystems to co-develop COVID-19 RNA Vaccine

              Details:

              Under this collaboration, PNI will be responsible for development of the mRNA-LNP vaccine and CanSinoBIO will be responsible for pre-clinical testing, human clinical trials, regulatory approval and commercialization.

              Lead Product(s): COVID-19 mRNA-LNP vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Vaccine

              Partner/Sponsor/Collaborator: CanSino Biologics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 21, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY